Susquehanna Fundamental Investments LLC Invests $346,000 in Editas Medicine, Inc. (NASDAQ:EDIT)

Susquehanna Fundamental Investments LLC bought a new position in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 272,430 shares of the company's stock, valued at approximately $346,000. Susquehanna Fundamental Investments LLC owned approximately 0.33% of Editas Medicine at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dark Forest Capital Management LP lifted its stake in Editas Medicine by 66.9% in the fourth quarter. Dark Forest Capital Management LP now owns 32,787 shares of the company's stock worth $42,000 after purchasing an additional 13,138 shares during the last quarter. XTX Topco Ltd boosted its stake in Editas Medicine by 99.9% in the fourth quarter. XTX Topco Ltd now owns 105,056 shares of the company's stock valued at $133,000 after acquiring an additional 52,498 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Editas Medicine during the 4th quarter valued at about $303,000. Renaissance Technologies LLC purchased a new stake in shares of Editas Medicine during the fourth quarter valued at $1,843,000. Finally, Invesco Ltd. lifted its holdings in shares of Editas Medicine by 9.2% during the fourth quarter. Invesco Ltd. now owns 100,164 shares of the company's stock worth $127,000 after purchasing an additional 8,448 shares during the period. Institutional investors own 71.90% of the company's stock.

Wall Street Analyst Weigh In

EDIT has been the topic of a number of analyst reports. HC Wainwright began coverage on Editas Medicine in a research report on Monday, April 28th. They set a "buy" rating and a $3.00 target price on the stock. Cantor Fitzgerald raised Editas Medicine from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 29th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating, three have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Editas Medicine presently has an average rating of "Hold" and an average price target of $6.54.

Editas Medicine Stock Up 4.0 %

Shares of Editas Medicine stock traded up $0.06 during midday trading on Friday, hitting $1.45. The company's stock had a trading volume of 962,959 shares, compared to its average volume of 2,563,538. The stock has a 50-day simple moving average of $1.38 and a 200-day simple moving average of $1.73. The firm has a market capitalization of $120.96 million, a P/E ratio of -0.56 and a beta of 2.15. Editas Medicine, Inc. has a 1-year low of $0.91 and a 1-year high of $6.69.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The firm had revenue of $30.60 million during the quarter, compared to the consensus estimate of $37.17 million. During the same quarter last year, the business earned ($0.23) EPS. As a group, sell-side analysts predict that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.

Editas Medicine Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.